Promises and challenges for the development of Listeria monocytogenes-based immunotherapies

References

• Katano M, Morisaki T. The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res.18(5D), 3917–3925 (1998).
   PubMed Web of Science ®Google Scholar
• Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed. Pharmacother.61(6), 299–305 (2007).
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol.7(3), 179–190 (2007).
   PubMed Web of Science ®Google Scholar
• O’Neill LA. How Toll-like receptors signal: what we know and what we don’t know. Curr. Opin. Immunol.18(1), 3–9 (2006).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature453(7198), 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Berg T, Desager JP et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology42(3), 724–731 (2005).
   PubMed Web of Science ®Google Scholar
• Luo Y, Yamada H, Chen X et al. Recombinant Mycobacterium bovis bacillus Calmette–Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin. Exp. Immunol.137(1), 24–34 (2004).
   PubMed Web of Science ®Google Scholar
• King I, Bermudes D, Lin S et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum. Gene Ther.13(10), 1225–1233 (2002).
   PubMed Web of Science ®Google Scholar
• Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res.57(20), 4537–4544 (1997).
   PubMed Web of Science ®Google Scholar
• Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J. Pathol.208(2), 290–298 (2006).
   PubMed Web of Science ®Google Scholar
• Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med.10(9), 887–892 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers HW, Unanue ER. Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect. Immun.61(12), 5090–5096 (1993).
   PubMed Web of Science ®Google Scholar
• Pamer EG. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol.4(10), 812–823 (2004).
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Shen H. Innate and adaptive immune responses to Listeria monocytogenes: a short overview. Microbes Infect.9(10), 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace ME, Smyth MJ. The role of natural killer cells in tumor control – effectors and regulators of adaptive immunity. Springer Semin. Immunopathol.27(1), 49–64 (2005).
   PubMed Web of Science ®Google Scholar
• Lanier LL. Evolutionary struggles between NK cells and viruses. Nat. Rev. Immunol.8(4), 259–268 (2008).
   PubMed Web of Science ®Google Scholar
• Bahjat KS, Prell RA, Allen HE et al. Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J. Immunol.179(11), 7376–7384 (2007).
   PubMedGoogle Scholar
• Shen H, Kanoh M, Maruyama S et al. Attenuated Listeria infection activates natural killer cell cytotoxicity to regress melanoma growth in vivo. Microbiol. Immunol.52(2), 107–117 (2008).
   Google Scholar
• Yoshimura K, Jain A, Allen HE et al. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res.66(2), 1096–1104 (2006).
   PubMedGoogle Scholar
• Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity21(5), 733–741 (2004).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Tough DF. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev.19(1), 33–40 (2008).
   Google Scholar
• Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol.14(4), 432–436 (2002).
   PubMed Web of Science ®Google Scholar
• Beauregard KE, Lee KD, Collier RJ, Swanson JA. pH-dependent perforation of macrophage phagosomes by listeriolysin O from Listeria monocytogenes. J. Exp. Med.186(7), 1159–1163 (1997).
   PubMed Web of Science ®Google Scholar
• O’Riordan M, Yi CH, Gonzales R, Lee KD, Portnoy DA. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc. Natl Acad. Sci. USA99(21), 13861–13866 (2002).
   PubMed Web of Science ®Google Scholar
• Giedlin MA, Cook DN, Dubensky TW Jr. Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field’s Virology? Cancer Cell4(4), 241–243 (2003).
   Google Scholar
• Auerbuch V, Brockstedt DG, Meyer-Morse N, O’Riordan M, Portnoy DA. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med.200(4), 527–533 (2004).
   PubMed Web of Science ®Google Scholar
• Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med.200(4), 535–540 (2004).
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Saha SK, Vaidya SA et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med.200(4), 437–445 (2004).
   PubMed Web of Science ®Google Scholar
• Yang J, Yang M, Htut TM et al. Epstein–Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgt. Eur. J. Immunol.38(5), 1204–1214 (2008).
   PubMed Web of Science ®Google Scholar
• Carrero JA, Calderon B, Unanue ER. Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes. J. Exp. Med.203(4), 933–940 (2006).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA102(42), 15190–15194 (2005).
   PubMed Web of Science ®Google Scholar
• Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol.6(8), 769–776 (2005).
   PubMed Web of Science ®Google Scholar
• Mackaness GB. Cellular resistance to infection. J. Exp. Med.116, 381–406 (1962).
   PubMed Web of Science ®Google Scholar
• Bahjat KS, Liu W, Lemmens EE et al. Cytosolic entry controls CD8+ T cell potency during bacterial infection. Infect. Immun.74(11), 6387–6397 (2006).
   PubMedGoogle Scholar
• Hamilton SE, Badovinac VP, Khanolkar A, Harty JT. Listeriolysin O-deficient Listeria monocytogenes as a vaccine delivery vehicle: antigen-specific CD8 T cell priming and protective immunity. J. Immunol.177(6), 4012–4020 (2006).
   PubMed Web of Science ®Google Scholar
• Lauvau G, Vijh S, Kong P et al. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science294(5547), 1735–1739 (2001).
   PubMedGoogle Scholar
• Jung S, Unutmaz D, Wong P et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity17(2), 211–220 (2002).
   PubMed Web of Science ®Google Scholar
• Muraille E, Giannino R, Guirnalda P et al. Distinct in vivo dendritic cell activation by live versus killed Listeria monocytogenes. Eur. J. Immunol.35(5), 1463–1471 (2005).
   Google Scholar
• Belz GT, Smith CM, Eichner D et al. Cutting edge: conventional CD8 a+ dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol.172(4), 1996–2000 (2004).
   PubMed Web of Science ®Google Scholar
• den Haan JM, Lehar SM, Bevan MJ. CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med.192(12), 1685–1696 (2000).
   PubMed Web of Science ®Google Scholar
• Schnorrer P, Behrens GM, Wilson NS et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl Acad. Sci. USA103(28), 10729–10734 (2006).
   PubMed Web of Science ®Google Scholar
• Belz GT, Shortman K, Bevan MJ, Heath WR. CD8a+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J. Immunol.175(1), 196–200 (2005).
   PubMed Web of Science ®Google Scholar
• Villadangos JA, Heath WR. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin. Immunol.17(4), 262–272 (2005).
   PubMed Web of Science ®Google Scholar
• Allan RS, Waithman J, Bedoui S et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity25(1), 153–162 (2006).
   PubMed Web of Science ®Google Scholar
• Neuenhahn M, Kerksiek KM, Nauerth M et al. CD8a+ dendritic cells are required for efficient entry of Listeria monocytogenes into the spleen. Immunity25(4), 619–630 (2006).
   PubMedGoogle Scholar
• Warren SE, Mao DP, Rodriguez AE, Miao EA, Aderem A. Multiple Nod-like receptors activate caspase 1 during Listeria monocytogenes infection. J. Immunol.180(11), 7558–7564 (2008).
   PubMed Web of Science ®Google Scholar
• Cervantes J, Nagata T, Uchijima M, Shibata K, Koide Y. Intracytosolic Listeria monocytogenes induces cell death through caspase-1 activation in murine macrophages. Cell. Microbiol.10(1), 41–52 (2008).
   PubMedGoogle Scholar
• Guzman CA, Domann E, Rohde M et al. Apoptosis of mouse dendritic cells is triggered by listeriolysin, the major virulence determinant of Listeria monocytogenes. Mol. Microbiol.20(1), 119–126 (1996).
   PubMed Web of Science ®Google Scholar
• Ozoren N, Masumoto J, Franchi L et al. Distinct roles of TLR2 and the adaptor ASC in IL-1β/IL-18 secretion in response to Listeria monocytogenes. J. Immunol.176(7), 4337–4342 (2006).
   PubMedGoogle Scholar
• Khanna KM, McNamara JT, Lefrancois L. In situ imaging of the endogenous CD8 T cell response to infection. Science318(5847), 116–120 (2007).
   PubMedGoogle Scholar
• Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther.11(Suppl. 1), S10–S17 (2004).
   PubMed Web of Science ®Google Scholar
• Edelson BT, Cossart P, Unanue ER. Cutting edge: paradigm revisited: antibody provides resistance to Listeria infection. J. Immunol.163(8), 4087–4090 (1999).
   PubMed Web of Science ®Google Scholar
• Edelson BT, Unanue ER. Intracellular antibody neutralizes Listeria growth. Immunity14(5), 503–512 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens R, Lavoy A, Nordone S, Burkhard M, Dean GA. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine. Vaccine23(12), 1479–1490 (2005).
   Google Scholar
• Bouwer HG, Shen H, Fan X et al. Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response. Infect. Immun.67(1), 253–258 (1999).
   Google Scholar
• Tvinnereim AR, Hamilton SE, Harty JT. CD8+-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection. Infect. Immun.70(1), 153–162 (2002).
   Google Scholar
• Starks H, Bruhn KW, Shen H et al.Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol.173(1), 420–427 (2004).
   PubMed Web of Science ®Google Scholar
• Vijh S, Pilip IM, Pamer EG. Noncompetitive expansion of cytotoxic T lymphocytes specific for different antigens during bacterial infection. Infect. Immun.67(3), 1303–1309 (1999).
   PubMedGoogle Scholar
• Blair DA, Lefrancois L. Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells. Proc. Natl Acad. Sci. USA104(38), 15045–15050 (2007).
   Google Scholar
• Jensen ER, Selvakumar R, Shen H et al. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J. Virol.71(11), 8467–8474 (1997).
   PubMedGoogle Scholar
• Yoshimura K, Jain A, Allen HE et al. Selective targeting of anti-tumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res.66(2), 1096–1104 (2006).
   PubMedGoogle Scholar
• Brockstedt DG, Giedlin MA, Leong ML et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl Acad. Sci. USA101(38), 13832–13837 (2004).
   PubMed Web of Science ®Google Scholar
• Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med.1(5), 471–477 (1995).
   PubMed Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters C et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors Immortalized by HPV-16. J. Immunol.167, 6471–6479 (2001).
   PubMed Web of Science ®Google Scholar
• Liau LM, Jensen ER, Kremen T et al. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res.62, 2287–2293 (2002).
   PubMed Web of Science ®Google Scholar
• Craft N, Bruhn KW, Nguyen BD et al. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J. Immunol.175(3), 1983–1990 (2005).
   PubMed Web of Science ®Google Scholar
• Shen H, Slifka MK, Matloubian M et al. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc. Natl Acad. Sci. USA92(9), 3987–3991 (1995).
   PubMed Web of Science ®Google Scholar
• Farber JM, Ross WH, Harwig J. Health risk assessment of Listeria monocytogenes in Canada. Int. J. Food Microbiol.30(1–2), 145–156 (1996).
   PubMed Web of Science ®Google Scholar
• Farber JM, Peterkin PI. Listeria monocytogenes, a food-borne pathogen. Microbiol. Rev.55(3), 476–511 (1991).
   PubMedGoogle Scholar
• Low JC, Donachie W. A review of Listeria monocytogenes and listeriosis. Vet. J.153(1), 9–29 (1997).
   PubMed Web of Science ®Google Scholar
• Lorber B. Listeriosis. Clin. Infect. Dis.24(1), 1–9 (1997).
   PubMed Web of Science ®Google Scholar
• Rivero GA, Torres HA, Rolston KV, Kontoyiannis DP. Listeria monocytogenes infection in patients with cancer. Diagn. Microbiol. Infect. Dis.47(2), 393–398 (2003).
   PubMed Web of Science ®Google Scholar
• Safdar A, Armstrong D. Listeriosis in patients at a comprehensive cancer center, 1955–1997. Clin. Infect. Dis.37(3), 359–364 (2003).
   PubMed Web of Science ®Google Scholar
• Goossens PL, Milon G. Induction of protective CD8+ T lymphocytes by an attenuated Listeria monocytogenes actA mutant. Int. Immunol.4(12), 1413–1418 (1992).
   PubMedGoogle Scholar
• Portnoy DA, Auerbuch V, Glomski IJ. The cell biology of Listeria monocytogenes infection: the intersection of bacterial pathogenesis and cell-mediated immunity. J. Cell Biol.158(3), 409–414 (2002).
   PubMed Web of Science ®Google Scholar
• Tilney LG, Portnoy DA. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J. Cell Biol.109, 1597–1607 (1989).
   PubMed Web of Science ®Google Scholar
• Angelakopoulos H, Loock K, Sisul D et al. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun.70(7), 3592–3601 (2002).
   PubMed Web of Science ®Google Scholar
• Cossart P, Pizarro-Cerda J, Lecuit M. Invasion of mammalian cells by Listeria monocytogenes: functional mimicry to subvert cellular functions. Trends Cell Biol.13(1), 23–31 (2003).
   PubMed Web of Science ®Google Scholar
• Singh R, Paterson Y. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev. Vaccines5(4), 541–552 (2006).
   PubMed Web of Science ®Google Scholar
• Gray MJ, Freitag NE, Boor KJ. How the bacterial pathogen Listeria monocytogenes mediates the switch from environmental Dr. Jekyll to pathogenic Mr. Hyde. Infect. Immun.74(5), 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Vazquez-Boland JA, Kuhn M, Berche P et al. Listeria pathogenesis and molecular virulence determinants. Clin. Microbiol. Rev.14(3), 584–640 (2001).
   PubMed Web of Science ®Google Scholar
• Souders NC, Sewell DA, Pan ZK et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun.7(2), 1–12 (2007).
   Google Scholar
• Curtiss R 3rd. Bacterial infectious disease control by vaccine development. J. Clin. Invest.110(8), 1061–1066 (2002).
   Google Scholar
• Stritzker J, Janda J, Schoen C et al. Growth, virulence, and immunogenicity of Listeria monocytogenes aro mutants. Infect. Immun.72(10), 5622–5629 (2004).
   PubMed Web of Science ®Google Scholar
• Stritzker J, Schoen C, Goebel W. Enhanced synthesis of internalin A in aro mutants of Listeria monocytogenes indicates posttranscriptional control of the inlAB mRNA. J. Bacteriol.187(8), 2836–2845 (2005).
   Google Scholar
• Thompson RJ, Bouwer HG, Portnoy DA, Frankel FR. Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires D-alanine for growth. Infect. Immun.66(8), 3552–3561 (1998).
   PubMed Web of Science ®Google Scholar
• Rayevskaya MV, Frankel FR. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J. Virol.75(6), 2786–2791 (2001).
   Google Scholar
• Rayevskaya M, Kushnir N, Frankel FR. Safety and immunogenicity in neonatal mice of a hyperattenuated Listeria vaccine directed against human immunodeficiency virus. J. Virol.76(2), 918–922 (2002).
   PubMedGoogle Scholar
• Friedman RS, Frankel FR, Xu Z, Lieberman J. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J. Virol.74(21), 9987–9993 (2000).
   Google Scholar
• Jiang S, Rasmussen RA, Nolan KM et al. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine25(42), 7470–7479 (2007).
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao X, Higgins DE, Frankel FR. Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity. Infect. Immun.73(8), 5065–5073 (2005).
   Google Scholar
• Li Z, Zhao X, Zhou C, Gu B, Frankel FR. A truncated Bacillus subtilis dal gene with a 3á ssrA gene tag regulates the growth and virulence of racemase-deficient Listeria monocytogenes. Microbiology152(Pt 10), 3091–3102 (2006).
   Google Scholar
• Li Z, Zhang M, Zhou C et al. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J. Immunol.180(4), 2504–2513 (2008).
   PubMed Web of Science ®Google Scholar
• Shen H, Miller JF, Fan X et al. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell92(4), 535–545 (1998).
   PubMedGoogle Scholar
• Dietrich G, Bubert A, Gentschev I et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol.16, 181–185 (1998).
   PubMed Web of Science ®Google Scholar
• Schoen C, Kolb-Maurer A, Geginat G et al. Bacterial delivery of functional messenger RNA to mammalian cells. Cell. Microbiol.7(5), 709–724 (2005).
   PubMed Web of Science ®Google Scholar
• Pilgrim S, Stritzker J, Schoen C et al. Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery. Gene Ther.10(24), 2036–2045 (2003).
   PubMed Web of Science ®Google Scholar
• Loeffler DI, Schoen CU, Goebel W, Pilgrim S. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Infect. Immun.74(7), 3946–3957 (2006).
   PubMed Web of Science ®Google Scholar
• Souders NC, Verch T, Paterson Y. In vivo bactofection: listeria can function as a DNA-cancer vaccine. DNA Cell Biol,25(3), 142–151 (2006).
   PubMed Web of Science ®Google Scholar
• Datta SK, Okamoto S, Hayashi T et al. Vaccination with irradiated listeria induces protective T cell immunity. Immunity25(1), 143–152 (2006).
   Google Scholar
• Brockstedt DG, Bahjat KS, Giedlin MA et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat. Med.11(8), 853–860 (2005).
   PubMed Web of Science ®Google Scholar
• Lauer P, Hanson B, Lemmens EE et al. Constitutive activation of the PrfA regulon enhances the potency of live-attenuated and KBMA Listeria monocytogenes-based vaccines. Infect. Immun.76(8), 3742–3753 (2008).
   PubMedGoogle Scholar
• Lankowski AJ, Hohmann EL. Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector. J. Infect. Dis.195(8), 1203–1211 (2007).
   Google Scholar
• Camilli A, Tilney LG, Portnoy DA. Dual roles of plcA in Listeria monocytogenes pathogenesis. Mol. Microbiol.8(1), 143–157 (1993).
   PubMedGoogle Scholar
• Lauer P, Chow MY, Loessner MJ, Portnoy DA, Calendar R. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J. Bacteriol.184(15), 4177–4178 (2002).
   PubMed Web of Science ®Google Scholar
• Brunt LM, Portnoy DA, Unanue ER. Presentation of Listeria monocytogenes to CD8+ T cells requires secretion of hemolysin and intracellular bacterial growth. J. Immunol.145(11), 3540–3546 (1990).
   PubMed Web of Science ®Google Scholar
• Sewell DA, Douven D, Pan ZK, Rodriguez A, Paterson Y. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch. Otolaryngol. Head Neck Surg.130(1), 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Souders NC, Sewell DA, Pan ZK et al.Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun.7, 2(2007).
   PubMedGoogle Scholar
• Decatur AL, Portnoy DA. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science290, 992–995 (2000).
   PubMed Web of Science ®Google Scholar
• Sewell DA, Shahabi V, Gunn GR 3rd et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res.64(24), 8821–8825 (2004).
   PubMed Web of Science ®Google Scholar
• Hussain SF, Paterson Y. CD4+CD25+ regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector. J. Immunother.27(5), 339–346 (2004).
   PubMed Web of Science ®Google Scholar
• Schnupf P, Portnoy DA, Decatur AL. Phosphorylation, ubiquitination and degradation of listeriolysin O in mammalian cells: role of the PEST-like sequence. Cell. Microbiol.8(2), 353–364 (2006).
   PubMed Web of Science ®Google Scholar
• Schnupf P, Portnoy DA. Listeriolysin O: a phagosome-specific lysin. Microbes Infect.9(10), 1176–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Shetron-Rama LM, Marquis H, Bouwer HG, Freitag NE. Intracellular induction of Listeria monocytogenes actA expression. Infect. Immun.70(3), 1087–1096 (2002).
   PubMed Web of Science ®Google Scholar
• Singh R, Dominiecki ME, Jaffee E, Paterson Y. Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol.175(6), 3663–3673 (2005).
   PubMed Web of Science ®Google Scholar
• Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res.67(5), 1887–1892 (2007).
   PubMed Web of Science ®Google Scholar
• Desvaux M, Hebraud M. The protein secretion systems in Listeria: inside out bacterial virulence. FEMS Microbiol. Rev.30(5), 774–805 (2006).
   Google Scholar
• Lenz LL, Portnoy DA. Identification of a second Listeria secA gene associated with protein secretion and the rough phenotype. Mol. Microbiol.45(4), 1043–1056 (2002).
   Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer7(2), 95–106 (2007).
   PubMed Web of Science ®Google Scholar
• Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res.65(18), 8059–8064 (2005).
   PubMed Web of Science ®Google Scholar
• Machiels JP, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res.61(9), 3689–3697 (2001).
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv. Immunol.90, 51–81 (2006).
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol.3(7), 611–618 (2002).
   PubMed Web of Science ®Google Scholar
• Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J. Immunother.30(3), 251–260 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg MV, Maris CH, Hipkiss EL et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood110(1), 186–192 (2007).
   PubMed Web of Science ®Google Scholar
• Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother.30(1), 1–15 (2007).
   PubMed Web of Science ®Google Scholar
• Minton NP. Clostridia in cancer therapy. Nat. Rev. Microbiol.1(3), 237–242 (2003).
   PubMed Web of Science ®Google Scholar
• Slobbe L, Lockhart E, O’Donnell MA et al. An in vivo comparison of bacillus Calmette–Guerin (BCG) and cytokine-secreting BCG vaccines. Immunology96(4), 517–523 (1999).
   PubMedGoogle Scholar
• O’Donnell MA, Aldovini A, Duda RB et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances g interferon production by splenocytes. Infect. Immun.62(6), 2508–2514 (1994).
   PubMed Web of Science ®Google Scholar
• Arnold J, de Boer EC, O’Donnell MA, Bohle A, Brandau S. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-g. J. Immunother.27(2), 116–123 (2004).
   PubMed Web of Science ®Google Scholar
• Wei SH, Yin W, An QX et al. A novel hepatitis C virus vaccine approach using recombinant bacillus Calmette-Guerin expressing multi-epitope antigen. Arch. Virol.153(6), 1021–1029 (2008).
   PubMed Web of Science ®Google Scholar
• Uno-Furuta S, Matsuo K, Tamaki S et al. Immunization with recombinant Calmette–Guerin bacillus (BCG)–hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice. Vaccine21(23), 3149–3156 (2003).
   PubMed Web of Science ®Google Scholar
• Edelman R, Palmer K, Russ KG et al. Safety and immunogenicity of recombinant bacille Calmette–Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine17(7–8), 904–914 (1999).
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu B, Wang Q et al. Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-g confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. FEMS Immunol. Med. Microbiol.51(3), 480–487 (2007).
   PubMedGoogle Scholar
• Agrawal N, Bettegowda C, Cheong I et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl Acad. Sci. USA101(42), 15172–15177 (2004).
   PubMed Web of Science ®Google Scholar
• Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl Acad. Sci. USA98(26), 15155–15160 (2001).
   PubMed Web of Science ®Google Scholar
• Radford KJ, Higgins DE, Pasquini S et al. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther.9(21), 1455–1463 (2002).
   PubMedGoogle Scholar
• Toso JF, Gill VJ, Hwu P et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol.20(1), 142–152 (2002).
   PubMed Web of Science ®Google Scholar
• Shata MT, Hone DM. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8+ T cells and antiviral protective immunity. J. Virol.75(20), 9665–9670 (2001).
   PubMed Web of Science ®Google Scholar
• Franzusoff A, Duke RC, King TH, Lu Y, Rodell TC. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin. Biol. Ther.5(4), 565–575 (2005).
   PubMed Web of Science ®Google Scholar
• Lu Y, Bellgrau D, Dwyer-Nield LD et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res.64(15), 5084–5088 (2004).
   PubMed Web of Science ®Google Scholar
• Haller AA, Lauer GM, King TH et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and core proteins. Vaccine25(8), 1452–1463 (2007).
   PubMed Web of Science ®Google Scholar
• Al-Mariri A, Tibor A, Lestrate P et al. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect. Immun.70(4), 1915–1923 (2002).
   PubMed Web of Science ®Google Scholar